Mivacurium in special patient groups

In special patient groups, drug response may be different from that in the healthy adult patient. Mivacurium dose requirements vary with age, and children require larger doses to obtain any given degree of block, but the elderly often require smaller doses. However, the dose requirements of the neonate do not necessarily differ greatly from those of the adult. There is a relationship between the duration of action of a bolus dose – as well as infusion requirements to maintain block – and the plasma cholinesterase activity. Patients with renal disease may have a decreased cholinesterase activity and may require smaller doses of mivacurium. Patients with severe liver disease may have a marked decrease in cholinesterase activity, and in these patients a substantially smaller dose of the drug may be needed to obtain and maintain any given degree of block. If the variation in dose requirements is kept in mind and the degree of block appropriately monitored, mivacurium may be used with safety in special patient groups, such as children, the elderly, or those with renal or hepatic impairment.

[1]  T. Taivainen,et al.  Recent developments in muscle relaxation in children , 1994 .

[2]  T. Sharpe,et al.  Neuromuscular and haemodynamic effects of mivacurium in elderly and young adult patients. , 1994, British journal of anaesthesia.

[3]  T. Taivainen,et al.  Pharmacodynamics of mivacurium in infants. , 1994, British journal of anaesthesia.

[4]  A. Al-Ghamdi,et al.  Dose-response relationships for edrophonium and neostigmine antagonism of mivacurium-induced neuromuscular block. , 1993, British journal of anaesthesia.

[5]  J. Hunter,et al.  Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis. , 1993, British journal of anaesthesia.

[6]  T. Taivainen,et al.  Accelerated onset and delayed recovery of neuromuscular block induced by mivacurium preceded by pancuronium in children. , 1993, Anesthesia and analgesia.

[7]  R. Welch,et al.  Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. , 1992, British journal of anaesthesia.

[8]  R. Mirakhur,et al.  Dose-response relationships for neostigmine antagonism of vecuronium-induced neuromuscular block in adults and the elderly. , 1992, British journal of anaesthesia.

[9]  J. Hunter,et al.  Use of mivacurium chloride by constant infusion in the anephric patient. , 1992, British journal of anaesthesia.

[10]  J. Hunter EDITORIAL I RESISTANCE TO NON-DEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS , 1991 .

[11]  F. McGowan,et al.  DOSE-RESPONSE RELATIONSHIP OF MIVACURIUM CHLORIDE (MIVACRON®) IN INFANTS DURING NITROUS OXIDE-HALOTHANE ANESTHESIA , 1991 .

[12]  D. Goldhill,et al.  Neuromuscular and clinical effects of mivacurium chloride in healthy adult patients during nitrous oxide-enflurane anaesthesia. , 1991, British journal of anaesthesia.

[13]  J. Hunter Resistance to non-depolarizing neuromuscular blocking agents. , 1991, British journal of anaesthesia.

[14]  O. Meretoja Neuromuscular Blocking Agents in Paediatric Patients: Influence of Age on the Response , 1990, Anaesthesia and intensive care.

[15]  D. R. Cook,et al.  Mivacurium Infusion Requirements in Pediatric Surgical Patients During Nitrous Oxide‐Halothane and During Nitrous Oxide‐Narcotic Anesthesia , 1990, Anesthesia and analgesia.

[16]  R. Miller,et al.  Pharmacokinetics and pharmacodynamics of atracurium in infants and children. , 1990, Anesthesiology.

[17]  C. Meistelman,et al.  Recovery from vecuronium neuromuscular blockade following neostigmine administration in infants, children, and adults during halothane anesthesia. , 1989, Anesthesiology.

[18]  J. Kirchner,et al.  Neuromuscular and cardiovascular effects of mivacurium chloride in surgical patients receiving nitrous oxide-narcotic or nitrous oxide-isoflurane anaesthesia , 1989, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[19]  T. Heier,et al.  Comparison of the neuromuscular block induced by mivacurium, suxamethonium or atracurium during nitrous oxide-fentanyl anaesthesia. , 1989, British journal of anaesthesia.

[20]  B. Jonson,et al.  Monitoring of physiological parameters during high frequency ventilation (HFV) , 1989, Acta anaesthesiologica Scandinavica. Supplementum.

[21]  R. Welch,et al.  In Vitro Metabolism of Mivacurium Chloride (BW B1090U) and Succinylcholine , 1989, Anesthesia and analgesia.

[22]  N. Goudsouzian,et al.  Neuromuscular and cardiovascular effects of mivacurium in children. , 1989, Anesthesiology.

[23]  B. Brandom,et al.  Clinical Pharmacology of Mivacurium Chloride (BW B1090U) in Children During Nitrous Oxide‐Halothane and Nitrous Oxide‐Narcotic Anesthesia , 1989, Anesthesia and analgesia.

[24]  W. Wargin,et al.  NEUROMUSCULAR EFFECTS AND PHARMACOKINETICS OF OOXACURIUM IN ELDERLY PATIENTS UNDER ISOFLURANE ANESTHESIA , 1988 .

[25]  Ronald D. Miller,et al.  The Pharmacodynamics and Pharmacokinetics of Vecuronium in Patients Anesthetized with Isoflurane with Normal Renal Function or with Renal Failure , 1988, Anesthesiology.

[26]  H. H. Ali,et al.  The Clinical Neuromuscular Pharmacology of Mivacurium Chloride (BW B1090U). A Short‐acting Nondepolarizing Ester Neuromuscular Blocking Drug , 1988, Anesthesiology.

[27]  G. Meakin,et al.  Comparison of atracurium-induced neuromuscular blockade in neonates, infants and children. , 1988, British journal of anaesthesia.

[28]  D. R. Cook,et al.  Pharmacokinetics of atracurium in anaesthetized infants and children. , 1986, British journal of anaesthesia.

[29]  C A Shanks,et al.  Pharmacokinetics of the nondepolarizing neuromuscular relaxants applied to calculation of bolus and infusion dosage regimens. , 1986, Anesthesiology.

[30]  R. Miller,et al.  Neuromuscular Effects of Atracurlum during Halothane—Nitrous Oxide and Enflurane—Nitrous Oxide Anesthesia in Humans , 1985, Anesthesiology.

[31]  P. Duvaldestin,et al.  Pharmacokinetics and Pharmacodynamics of Vecuronium (ORG NC 45) in Patients with Cirrhosis , 1985, Anesthesiology.

[32]  P. Gencarelli,et al.  Vecuronium Infusion Dose Requirements during Fentanyl and Halothane Anesthesia in Humans , 1985, Anesthesia and analgesia.

[33]  Ronald D. Miller,et al.  Vecuronium kinetics and dynamics in anesthetized infants and children , 1985, Clinical pharmacology and therapeutics.

[34]  F. Donati,et al.  CUMULATION OF VECURONIUM IN RENAL FAILURE , 1984 .

[35]  Ronald D. Miller,et al.  ATRACURIUM NEUROMUSCULAR BLOCKADE DURING HALOTHANE/N2O AND ENFLURANE/N2O ANESTHESIA IN HUMANS , 1984 .

[36]  R. Matteo,et al.  Distribution, Elimination, and Action of d‐Tubocurarine in Neonates, Infants, Children, and Adults , 1984, Anesthesia and analgesia.

[37]  R. Miller,et al.  Vecuronium‐induced Neuromuscular Blockade during Enflurane, Isoflurane, and Halothane Anesthesia in Humans , 1984, Anesthesiology.

[38]  D. Bevan,et al.  Neostigmine and Edrophonium as Antagonists of Pancuronium in Infants and Children , 1983, Anesthesiology.

[39]  L. Barvais,et al.  Clinical evaluation of atracurium besylate requirement for a stable muscle relaxation during surgery: lack of age-related effects. , 1983, Anesthesiology.

[40]  D. Moyes,et al.  EFFECTS OF LOW INTERMITTENT CONCENTRATIONS OF NITROUS OXIDE ON THE DEVELOPING RAT FETUS , 1983 .

[41]  R. Miller,et al.  Neuromuscular and cardiovascular effects of atracurium during nitrous oxide-fentanyl and nitrous oxide-isoflurane anaesthesia. , 1983, British journal of anaesthesia.

[42]  J. Hunter,et al.  Use of atracurium in patients with no renal function. , 1982, British journal of anaesthesia.

[43]  H. S. Chadwick RELATIVE LIDOCAINE AND BUPIVACAINE TOXICITY IN VENTILATED CATS , 1982 .

[44]  D. Stanski,et al.  Pharmacokinetics and Pharmacodynamics of d‐Tubocurarine in Infants, Children, and Adults , 1982, Anesthesiology.

[45]  P. Duvaldestin,et al.  Binding of tubocurarine, fazadinium, pancuronium and Org NC 45 to serum proteins in normal man and in patients with cirrhosis. , 1982, British journal of anaesthesia.

[46]  D. Stanski,et al.  Pharmacokinetics of edrophonium in anephric and renal transplant patients. , 1981, British journal of anaesthesia.

[47]  R. Marsh,et al.  Recovery from pancuronium , 1980, Anaesthesia.

[48]  L. Sheiner,et al.  Pyridostigmine kinetics with and without renal function , 1980, Clinical pharmacology and therapeutics.

[49]  N. Goudsouzian Maturation of neuromuscular transmission in the infant. , 1980, British journal of anaesthesia.

[50]  D. Newton,et al.  Influence of halothane and enflurane on the neuromuscular effects of ORG NC 45 in man. , 1980, British Journal of Anaesthesia.

[51]  L. Sheiner,et al.  Renal function and the pharmacokinetics of neostigmine in anesthetized man. , 1979 .

[52]  D. Cullen,et al.  Renal failure and postoperative respiratory failure: recurarization? , 1976, British journal of anaesthesia.

[53]  L. Strunin,et al.  Althesin and pancuronium in chronic liver disease. , 1975, British journal of anaesthesia.

[54]  D. R. Cook,et al.  Neuromuscular Blocking Effects of Succinylcholine in Infants and Children , 1975, Anesthesiology.

[55]  M. Ghoneim,et al.  Binding of d‐Tubocurarine to Plasina Proteins in Normal Man and in Patients with Hepatic or Renal Disease , 1973, Anesthesiology.

[56]  B. Friis‐Hansen Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth. , 1971, Pediatrics.

[57]  J. Dundee,et al.  Resistance to d-tubocurarine chloride in the presence of liver damage. , 1953, Lancet.